What is the current stock price of hVIVO plc (OPORF)?

As of the latest market data, hVIVO plc (OPORF) is trading at $0.09. The stock has seen a loss of 0.00% today.

Does hVIVO plc (OPORF) pay a dividend?

Based on current data, hVIVO plc does not have a confirmed active dividend policy.

What is the market cap of hVIVO plc?

The current market capitalization of hVIVO plc (OPORF) is approximately unavailable.

OPORF

hVIVO plc·Healthcare

0.09

0.000%(+0.00)

Market Closed

0.11

24.530%(+0.02)

After Hours

Last Updated: — ET

52W L: $0.0952W H: $0.35

OPORF NEWS

proactiveinvestors.co.uk

Feb 12

hVIVO surges 50% in two days as ILiAD funding boosts contract hopes

hVIVO PLC (AIM:HVO) shares have jumped 50% in two days to 9.13p after ILiAD Biotechnologies secured $115 million in Series B financing, strengthening expectations that a previously signed letter of intent could convert into a full contract. In a flash note, Stifel said the fundraising clears a key hurdle that had prevented hVIVO from converting a January 2025 letter of intent to run a pivotal phase III human challenge trial for ILiAD's BPZE1 intranasal pertussis vaccine.

seekingalpha.com

Jan 31

hVIVO plc (OPORF) Q4 2025 Sales/Trading Call Transcript

proactiveinvestors.co.uk

Jan 29

City broker eyes turning point as hVIVO posts stronger than anticipated update

After hVIVO PLC (AIM:HVO) reported annual revenue of £46.7 million, in line with market expectations, City brokers were assessing whether the company is turning a corner after a difficult year. Broker Peel Hunt took a positive view, highlighting a strong fourth quarter, improved cost discipline and the benefit of cancellation fees with no associated variable costs.

proactiveinvestors.co.uk

Jan 29

hVIVO cheers stronger-than-expected delivery in 2025

hVIVO PLC (AIM:HVO) told investors it expects to report revenue of approximately £46.7 million for the year, ended 31 December, in line with market expectations. Earnings (adjusted EBITDA) margin is anticipated to be a low positive single-digit, which is ahead of previous guidance.

Company Profile

hVIVO plc operates as a pharmaceutical service and contract research company. The company is involved in testing vaccines and antivirals using human challenge clinical trials. It provides services to big pharma, biotech, government, and public health organizations. The company has a portfolio of human challenge study models for conditions, such as RSV, flu, human rhinovirus, asthma, malaria, cough, and COPD, as well as developing COVID-19 human challenge study model. In addition, the company is developing a database of infectious disease progression data that include Disease in Motion platform, which comprises unique datasets, such as clinical, immunological, virological, and digital (wearable) biomarkers. The Disease in Motion platform has various potential applications across a range of end users, including big technology, wearables, pharma, and biotech companies. Further, the company provides preclinical and early clinical research services; sales and marketing services; and biometry, data management, and statistics to its various European pharmaceutical clients, as well as drug development consultancy and services, including CMC (chemistry, manufacturing, and controls), and PK and medical writing to a range of European clients. The company was formerly known as Open Orphan Plc and changed its name to hVIVO plc in October 2022. hVIVO plc is headquartered in London, the United Kingdom.

Sector

Healthcare

Industry

Biotechnology

Employees

301

IPO Date

2020-06-05

Beta

1.67

Websitewww.hvivo.com↗